Human medicines European public assessment report (EPAR): Vaborem, meropenem,vaborbactam, Date of authorisation: 20/11/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Waylivra, volanesorsen, Date of authorisation: 03/05/2019, Revision: 8, Status: Authorised

Outcome of written procedures finalised during the period from 4 December 2025 to 3 March 2026

EMA traineeship programme informative session, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 April 2026, 10:00 (CEST) to 14 April 2026, 11:00 (CEST)

Veterinary medicines European public assessment report (EPAR): Cunitraxx, fenbendazole, Status: Application withdrawn

PSUSA/00000402/202506

Human medicines European public assessment report (EPAR): Ebglyss, lebrikizumab, Date of authorisation: 16/11/2023, Revision: 7, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, spesolimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000232315

Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Date of authorisation: 25/10/2012, Revision: 38, Status: Authorised